Lipvas Gold 10 Capsule is a combination medication containing Aspirin (75 mg), Atorvastatin (10 mg), and Clopidogrel (75 mg), indicated for the prevention of cardiovascular events in patients at high risk of atherosclerotic cardiovascular disease. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase, thereby reducing thromboxane A2 production and platelet aggregation. Atorvastatin, a statin class drug, functions by inhibiting HMG-CoA reductase, leading to decreased cholesterol synthesis and lowering low-density lipoprotein (LDL) cholesterol levels. Clopidogrel, another antiplatelet agent, selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, preventing platelet activation and aggregation. The combined effect of these agents helps reduce the risk of myocardial infarction, stroke, and other thrombotic complications in patients with established cardiovascular disease or multiple risk factors. Lipvas Gold 10 Capsule should be used under medical supervision, considering potential contraindications such as active bleeding, hypersensitivity to any component, or severe liver impairment. Regular monitoring of liver function, lipid profile, and bleeding parameters is recommended during therapy. This combination therapy offers a comprehensive approach to cardiovascular risk management by targeting lipid levels and platelet function simultaneously.